Innovative Technologies in Biological Systems

Their core work

INNOPROT is a Spanish biotech SME based in Derio (Basque Country) that develops microfluidic devices and nano-enabled surfaces for biological and bioanalytical applications. Their core work involves scaling up micro- and nanofabrication technologies — particularly roll-to-roll production methods — to move lab-stage bioanalytical devices toward industrial manufacturing. They contribute device validation, materials testing, and quality management expertise to EU consortia working on next-generation diagnostic and analytical platforms.

What they specialise in

How they've shifted over time

INNOPROT's early H2020 work (2015-2019) centered on large-scale micro- and nanofabrication for bioanalytical devices, with R2R Biofluidics as their entry point. By 2020, their focus sharpened toward nano-enabled surfaces, membranes, and the industrial upscaling of microfluidic devices — moving further down the manufacturing readiness chain. The trajectory shows a clear shift from participating in fundamental fabrication research toward applied device validation, quality management, and regulatory readiness.

INNOPROT is moving toward industrialization-ready microfluidics — expect them to seek partners in manufacturing scale-up, regulatory compliance, and commercial deployment of nano-enabled diagnostic devices.

How they like to work

INNOPROT has never coordinated an H2020 project — they join as a participant or third party, contributing specialized technical capabilities to larger consortia. With 41 unique partners across 12 countries from just 3 projects, they operate in large, diverse consortia (typical for Innovation Actions). This profile suggests a reliable specialist contributor that brings focused technical skills rather than project management ambition.

Despite only 3 projects, INNOPROT has built a broad network of 41 partners across 12 countries, indicating participation in large international consortia. Their Basque Country base connects them well to both Southern European and wider EU research ecosystems.

What sets them apart

INNOPROT sits at the intersection of nanotechnology and biological systems — a niche that few SMEs occupy with hands-on fabrication and validation capability. Their strength is bridging the gap between lab-scale nano-enabled devices and industrial-scale production through roll-to-roll methods. For consortium builders, they offer a private-sector partner who can handle device validation, materials testing, and quality management — the unglamorous but critical work that moves prototypes toward market.

Highlights from their portfolio

• NextGenMicrofluidics
  Their most recent and longest project (2020-2025), representing the clearest expression of their current strategic direction in nano-enabled microfluidic upscaling.
• R2R Biofluidics
  Their largest funded project (EUR 295,516) and their entry into H2020, establishing their roll-to-roll nanofabrication credentials.